We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the effects of the U.S. Medicare Part D redesign.
Blood thinner drug Eliquis’ sales of $3.56 billion were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap.
Multiple myeloma (MM) drug Revlimid revenues plummeted 44% to $936 million due to lower demand on account of generic erosion.
MM drug Pomalyst generated sales of $658 million, down 24% year over year. Leukemia drug Sprycel sales nosedived 53% year over year to $175 million due to generic competition. Abraxane revenues declined 52% to $105 million.
While drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base, an important point to consider is that the legacy portfolio sales accounted for 50% of total sales in the first quarter.
Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. However, BMY faces competition from large pharma companies like Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
The immuno-oncology space is dominated by Merck’s blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 50% of its MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 14% year to date compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.45x forward earnings, lower than its mean of 8.86x and the large-cap pharma industry’s 15.09X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved down to $6.76 from $6.89 in the past 60 days and that for 2026 is down five cents.
Image: Shutterstock
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Key Takeaways
Bristol Myers’ (BMY - Free Report) legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane.
Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the effects of the U.S. Medicare Part D redesign.
Blood thinner drug Eliquis’ sales of $3.56 billion were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap.
Multiple myeloma (MM) drug Revlimid revenues plummeted 44% to $936 million due to lower demand on account of generic erosion.
MM drug Pomalyst generated sales of $658 million, down 24% year over year. Leukemia drug Sprycel sales nosedived 53% year over year to $175 million due to generic competition. Abraxane revenues declined 52% to $105 million.
While drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base, an important point to consider is that the legacy portfolio sales accounted for 50% of total sales in the first quarter.
Competition for BMY’s Key Drugs
BMY’s growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others.
Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. However, BMY faces competition from large pharma companies like Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
The immuno-oncology space is dominated by Merck’s blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 50% of its MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 14% year to date compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.45x forward earnings, lower than its mean of 8.86x and the large-cap pharma industry’s 15.09X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved down to $6.76 from $6.89 in the past 60 days and that for 2026 is down five cents.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.